Platelet CD40 ligand and bleeding during P2Y12 inhibitor treatment in acute coronary syndrome

Antiplatelet therapy through inhibition of the adenosine diphosphate (ADP)/P2Y12 pathway is commonly used in the treatment of acute coronary syndrome (ACS). Although efficient in preventing platelet activation and thrombus formation, it increases the risk of bleeding complications. In patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Grosdidier, Charlotte, Blanz, Kelly D., Deharo, Pierre, Bernot, Denis, Poggi, Marjorie, Bastelica, Delphine, Wolf, Dennis, Duerschmied, Daniel, Grino, Michel, Cuisset, Thomas, Alessi, Marie‐Christine, Canault, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles: Thrombosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781928/
https://www.ncbi.nlm.nih.gov/pubmed/31624788
http://dx.doi.org/10.1002/rth2.12244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781928/
https://www.ncbi.nlm.nih.gov/pubmed/31624788
http://dx.doi.org/10.1002/rth2.12244

Ejemplares similares